Targeted drug takes aim at Hard-to-Treat lung cancer
NCT ID NCT06933329
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests an experimental drug called zelenectide pevedotin in 73 people with advanced or metastatic non-small cell lung cancer that has a specific genetic change (NECTIN4 amplification) and has already been treated with at least one prior therapy. The drug is given intravenously on days 1 and 8 of each 21-day cycle. The main goal is to see how many patients' tumors shrink or disappear, while also monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
zelenectide pevedotin (BT8009)
What this could lead to
If successful, this could point toward a new treatment option for people with a specific genetic subtype of advanced lung cancer that has stopped responding to standard therapies.
What could go wrong
This is a mid-stage trial with only 73 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors in enough patients to move forward.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Complejo Hospitalario Universitario A Coruña
A Coruña, 15006, Spain
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Institut Curie
Paris, 75005, France